Literature DB >> 16652032

Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial.

Kathleen Mulligan1, Robert A Parker, Lauren Komarow, Steven K Grinspoon, Pablo Tebas, Gregory K Robbins, Ronenn Roubenoff, Michael P Dubé.   

Abstract

INTRODUCTION: Although peripheral fat loss is a consistent feature of HIV-associated lipodystrophy, less is known about whether changes in central and peripheral fat occur in tandem or independently over time. We examined intraindividual changes in dual-energy x-ray absorptiometry (DEXA) and anthropometry data over 64 weeks after initiation of antiretroviral therapy (ART).
METHODS: In ACTG 384, ART-naive subjects were randomized to receive didanosine and stavudine or zidovudine and lamivudine plus efavirenz, nelfinavir, or both. In the metabolic substudy A5005S (N= 329), waist, hip, thigh, and arm circumferences were measured in triplicate. DEXA scanning was performed in 157 subjects.
RESULTS: Individual changes in limb and trunk fat at week 64 correlated positively (R =.72, P <.001). Most subjects had directionally concordant changes in limb and trunk fat (36% gained and 32% lost in both regions). In 26%, trunk fat increased while limb fat decreased, whereas the reverse occurred in only 6% (P <.001). Changes in waist and hip circumferences also correlated positively (R =.62, P <.001). The proportion of subjects with waist/hip ratio more than .95 (men) or .90 (women) was 34% at baseline and 47% at week 64 (P =.003). In those who developed increased waist/hip ratio, 76% had increased waist circumference.
CONCLUSIONS: Individual results obtained by both anthropometry and DEXA show diverse patterns of fat gain and loss over 64 weeks after initiation of ART, but changes tended to occur in the same direction. Increased waist/hip ratio was predominantly associated with increased waist circumference. There was no evidence that central fat accumulation and peripheral fat loss are linked in most subjects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652032     DOI: 10.1097/01.qai.0000214811.72916.67

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  25 in total

Review 1.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Authors:  Mustafa A Noor
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

Review 2.  Considering metabolic issues when initiating HIV therapy.

Authors:  David Alain Wohl
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

3.  Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.

Authors:  Kristine M Erlandson; Douglas Kitch; Camlin Tierney; Paul E Sax; Eric S Daar; Pablo Tebas; Kathleen Melbourne; Belinda Ha; Nasreen C Jahed; Grace A McComsey
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

4.  Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.

Authors:  Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

5.  Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults.

Authors:  P Freitas; D Carvalho; A C Santos; J Mesquita; F Correia; S Xerinda; R Marques; E Martinez; A Sarmento; J L Medina
Journal:  J Endocrinol Invest       Date:  2011-07-05       Impact factor: 4.256

6.  Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART).

Authors:  N Sunil Kumar; J Shashibhushan; K Venugopal; Huggi Vishwanatha; Mahesh Menon
Journal:  J Clin Diagn Res       Date:  2015-07-01

7.  Regional anthropometry changes in antiretroviral-naïve persons initiating a Zidovudine-containing regimen in Mbarara, Uganda.

Authors:  Vanessa Thompson; Bitekyerezo Medard; Kabanda Taseera; Ali J Chakera; Irene Andia; Nneka Emenyonu; Peter W Hunt; Jeffrey Martin; Rebecca Scherzer; Sheri D Weiser; David R Bangsberg; Phyllis C Tien
Journal:  AIDS Res Hum Retroviruses       Date:  2011-02-14       Impact factor: 2.205

Review 8.  The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Authors:  Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine
Journal:  Toxicol Pathol       Date:  2009-01-26       Impact factor: 1.902

9.  Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial.

Authors:  Fred R Sattler; Natasa Rajicic; Kathleen Mulligan; Kevin E Yarasheski; Susan L Koletar; Andrew Zolopa; Beverly Alston Smith; Robert Zackin; Bruce Bistrian
Journal:  Am J Clin Nutr       Date:  2008-11       Impact factor: 7.045

10.  Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy.

Authors:  Eugene Mutimura; Aimee Stewart; Paul Rheeder; Nigel John Crowther
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.